“Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies”, J of Skin, vol. 4, no. 5, p. s42, Sep. 2020, doi: 10.25251/skin.4.supp.42.